Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL31P34 (ribosomal protein L31 pseudogene 34) refers to a non-coding pseudogene related to the ribosomal protein L31 gene, which is a component of the large 60S ribosomal subunit. Unlike the parent gene RPL31, RPL31P34 is a processed pseudogene without evidence of translation into a functional ribosomal protein. Pseudogenes such as RPL31P34 typically result from genomic duplication or retrotransposition events and may consist of incomplete fragments of the original gene sequence. They are generally dispersed throughout the genome, do not contribute to ribosome structure or function, and are not considered viable therapeutic, diagnostic, or biomarker targets[2][3][1]. RPL31P34 is a non-functional pseudogene related to ribosomal protein L31, not a receptor or protein-coding gene, and is not considered a therapeutic target, diagnostic biomarker, or subject of drug interaction or safety concern.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L31 pseudogene 34 (RPL31P34).